ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / APUS / insiders
AZTR (33) TRAW (31) XBIO (32) CANF (25) ⌘ Pro Terminal β†’

Apimeds Pharmaceuticals US Inc. (APUS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.89 -3.99% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.86

Apimeds Pharmaceuticals US Inc. (APUS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $4.6M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APUS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.89 (-3.99% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, APUS ranks #552 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does APUS compare to AZTR and TRAW in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -6.2%. By comparison, AZTR (Azitra Inc) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APUS?
β–Ό

Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $33.4M in revenue (+834.2% YoY), -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.86 (-0.91%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (37/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D+
Cash (8)Whales (3)SEC (10)Macro (11)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.3% Base Target
$63 Bull$3 Base$2 Bear
πŸ“¬ FREE APUS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for APUS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
πŸ” WHY APUS SCORES 37/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 42.9 (NEUTRAL RANGE)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
45
Grade D$4.62-26.2% Next Q
Q2 (-2Q)
42
Grade D$3.41-10.6% Next Q
Q3 (-1Q)
40
Grade D$3.05-5.2% Next Q
Current
37
Grade D-$2.89-8.1% Hist 90D Ξ±
Trajectory: D (45) β†’ D- (37)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a APUS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While APUS currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($3.03) forces dealer call-delta covering toward $62.69.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APUSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAPUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

APUS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (APUS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on APUS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APUS)

  • βœ“Walkthrough of APUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
APUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.63%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $3.21H $3.21L $2.89C $2.89VOL 21.5K
RES: $12.46SUP: $-1.30SMA50: $3.63SMA200: $10.76
$63.77$46.90$30.02$13.15$-3.73RES $12.46SUP $-1.30$2.892026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ APUS Butterfly Map β†’ + Track APUS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +834.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on APUS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for APUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for APUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APUS)

Health Care Rank #552 of 1015 βš”οΈ AZTR vs APUS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (APUS vs. AZTR, TRAW, XBIO, CANF)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Apimeds Pharmaceuticals US Inc. (APUS) ranks #552 by composite RQD confidence (37/100, grade D-) and #951 by equity capitalization ($4.6M). Within this direct 5-issuer industry benchmark cohort, APUS leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and β€” gross margin. APUS currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
APUS ACTIVE
Apimeds Pharmaceuticals US Inc.
D- 37/100 β€” β€” -6.2% -3.99% $4.6M Benchmark Subject
AZTR
Azitra Inc
E 33/100 β€” β€” -35.0% +8.72% $4.7M /aztr-vs-apus β†’
TRAW
Traws Pharma Inc.
E 31/100 β€” β€” -35.0% +1.45% $4.5M /traw-vs-apus β†’
XBIO
Xenetic Biosciences Inc.
E 32/100 β€” β€” -30.3% +0.49% $4.8M /xbio-vs-apus β†’
CANF
Can-Fite Biopharma Ltd each representing two (2)
E 25/100 β€” β€” -35.0% +0.62% $4.9M /canf-vs-apus β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001894525 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported GAAP revenue of $33.4M (+834.2% vs. FY2024 revenue of $3.6M , and +1493.8% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-1124.6% YoY). On the balance sheet, APUS closed FY2025 with $164.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $33.4M -$6.0M -$8.9M -$9.0M $164.2M β€”
FY2024 (FY) 2024-12-31 $3.6M -$1.4M -$733.5K -$733.5K $13.1K β€”
FY2023 (FY) 2023-12-31 $2.1M -$777.7K -$627.8K -$627.8K β€” β€”

3. APUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.89 (-3.99% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, APUS ranks #552 in composite RQD confidence.

How does APUS compare to AZTR and TRAW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -6.2%. By comparison, AZTR (Azitra Inc) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APUS?

Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $33.4M in revenue (+834.2% YoY), -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APUS trading relative to its 50-day, 200-day, and 52-week technical levels?

APUS last traded at $2.89 (-3.99% on volume of 38,452 shares), positioning the stock -20.39% below its 50-day simple moving average ($3.63) and -73.14% below its 200-day simple moving average ($10.76). Across its 52-week range of $1.51 to $59.70, APUS sits at the 2.4% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($2.53 to $3.25).

Direct Sub-Reports: APUS RQD Cockpit APUS 12M Forecast APUS Earnings & Move APUS Dividends & DRIP APUS Insiders & 13F APUS Whale Options APUS Profit Sankey APUS News & Why
ROARABLE RATING BRIEF β€’ RQD 37/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

APUS β€” Apimeds Pharmaceuticals US Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Apimeds Pharmaceuticals US Inc. (APUS) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.89 (-3.99% 1D, market capitalization $4.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -6.2%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Apimeds Pharmaceuticals US Inc. Is listed on the NYSE and classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The issuer's market capitalization is $0.0B on a rounded basis, which conflicts with the $5.0M figure in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported $33.4M in annual revenue (up from $3.6M in FY2024, +834.2% YoY) and -$6.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.1M revenue, -$777.7K net income) through FY2025, APUS scaled operating cash flow to -$8.9M and free cash flow to -$9.0M, backed by $164.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.51 – $59.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), APUS carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can APUS sustain or expand its β€” operating margin and -6.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $33.4M and free cash flow of -$9.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is APUS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

APUS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Apimeds Pharmaceuticals US Inc. (APUS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to APUS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APUS Bull vs. Bear Conversation Board β€” What's Your Call at $2.89?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APUS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on APUS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $3.67 (+21.9%)
πŸ“Œ Pinned Debate

The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum t

Picked up a starter position in APUS in my $100K Virtual Cash book at $3.01. The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum traders.. Trading inside a $1.51–$59.70 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” APUS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.56 (-15.0%)
Spot @ $3.01

With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity t

Fading this rally in APUS at $3.01. With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity to fund operations without new capital.. With a beta of 1.0 and the stock sitting at $3.01 (52-wk range $1.51–$59.70), the easy multiple expansion is already priced in.

LIVE TAPE